
OpGen, Inc. – NASDAQ:OPGN
OpGen stock price today
OpGen stock price monthly change
OpGen stock price quarterly change
OpGen stock price yearly change
OpGen key metrics
Market Cap | 7.45M |
Enterprise value | 5.38M |
P/E | -0.08 |
EV/Sales | 1.33 |
EV/EBITDA | -0.12 |
Price/Sales | 0.70 |
Price/Book | 0.37 |
PEG ratio | N/A |
EPS | -14.46 |
Revenue | 2.67M |
EBITDA | -11.61M |
Income | -26.54M |
Revenue Q/Q | -81.59% |
Revenue Y/Y | -12.38% |
Profit margin | -1234.53% |
Oper. margin | -1129.63% |
Gross margin | -9.01% |
EBIT margin | -1129.63% |
EBITDA margin | -434.43% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOpGen stock price history
OpGen stock forecast
OpGen financial statements
Jun 2023 | 736.13K | -5.82M | -791.61% |
---|---|---|---|
Sep 2023 | 699.02K | -4.06M | -581.23% |
Dec 2023 | 1.06M | -17.04M | -1593.1% |
Mar 2024 | 168.14K | 386.03K | 229.58% |
Jun 2023 | 22434962 | 15.57M | 69.42% |
---|---|---|---|
Sep 2023 | 18134882 | 15.45M | 85.24% |
Dec 2023 | 1882274 | 13.44M | 714.23% |
Mar 2024 | 2970380 | 13.68M | 460.63% |
Jun 2023 | -4.75M | -367.31K | 1.50M |
---|---|---|---|
Sep 2023 | -2.92M | -101.73K | 27.53K |
Dec 2023 | -1.67M | -914 | 2.09M |
Mar 2024 | -1.08M | 0 | 199.72K |
OpGen alternative data
Aug 2023 | 85 |
---|---|
Sep 2023 | 85 |
Oct 2023 | 85 |
Nov 2023 | 85 |
Dec 2023 | 85 |
Jan 2024 | 85 |
Feb 2024 | 85 |
Mar 2024 | 85 |
Apr 2024 | 85 |
May 2024 | 85 |
Jun 2024 | 85 |
Jul 2024 | 85 |
OpGen other data
Period | Buy | Sel |
---|---|---|
Apr 2024 | 350000 | 0 |
Jul 2024 | 0 | 550000 |
Aug 2024 | 7645603 | 2663961 |
Patent |
---|
Grant Filling date: 6 Aug 2018 Issue date: 29 Dec 2020 |
Application Filling date: 11 Nov 2019 Issue date: 10 Sep 2020 |
Grant Filling date: 27 May 2015 Issue date: 12 Nov 2019 |
Quarter | Transcript |
---|---|
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 29 Mar 2023 | Q4 2022 Earnings Call Transcript |
Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Oliver Schacht Ph.D. (1971) Chief Executive Officer, Pres & Director | $565,870 |
Mr. Johannes Bacher (1969) Chief Operating Officer | $325,000 |
-
What's the price of OpGen stock today?
One share of OpGen stock can currently be purchased for approximately $4.7.
-
When is OpGen's next earnings date?
Unfortunately, OpGen's (OPGN) next earnings date is currently unknown.
-
Does OpGen pay dividends?
No, OpGen does not pay dividends.
-
How much money does OpGen make?
OpGen has a market capitalization of 7.45M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 31.11% to 3.42M US dollars.
-
What is OpGen's stock symbol?
OpGen, Inc. is traded on the NASDAQ under the ticker symbol "OPGN".
-
What is OpGen's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of OpGen?
Shares of OpGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are OpGen's key executives?
OpGen's management team includes the following people:
- Dr. Oliver Schacht Ph.D. Chief Executive Officer, Pres & Director(age: 54, pay: $565,870)
- Mr. Johannes Bacher Chief Operating Officer(age: 56, pay: $325,000)
-
How many employees does OpGen have?
As Jul 2024, OpGen employs 85 workers.
-
When OpGen went public?
OpGen, Inc. is publicly traded company for more then 10 years since IPO on 5 May 2015.
-
What is OpGen's official website?
The official website for OpGen is opgen.com.
-
Where are OpGen's headquarters?
OpGen is headquartered at 9717 Key West Avenue, Rockville, MD.
-
How can i contact OpGen?
OpGen's mailing address is 9717 Key West Avenue, Rockville, MD and company can be reached via phone at +240 8131260.
OpGen company profile:

OpGen, Inc.
opgen.comNASDAQ
85
Medical - Diagnostics & Research
Healthcare
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILĂšM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Rockville, MD 20850
CIK: 0001293818
ISIN: US68373L4068
CUSIP: 68373L307